Brought to you by Bristol Myers Squibb

Please join Bristol Myers Squibb for a product theater titled “A Treatment Option for Patients with Myelodysplastic Syndromes”.  This presentation will share information about a treatment option for myelodysplastic syndromes including an overview of MDS, ineffective erythropoiesis, the pivotal phase 3 trial design, efficacy, safety, dosing, and administration.

The program will be presented by Sara Tinsley, PhD, APRN on Thursday, April 22 at 2:00 PM Eastern.